Navigation Links
Dalton Pharma Services Announces Successful Completion of Health Canada Inspection
Date:2/1/2010

Dalton Announces Successful Completion of Health Canada Inspection and Compliance with European Directive for Manufacture and Testing of Drug Products Imported to the European Union.

Toronto, Ontario (PRWEB) February 1, 2010 -- Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced successful completion of its recent Health Canada audit. The Company has received a ‘Compliant’ rating following the regulatory agency’s inspection of Dalton’s GMP manufacturing facility.

The Establishment License issued by Health Canada will enable Dalton Pharma Services to continue to manufacture, test and ship sterile commercial products for its existing clients. In addition, Dalton’s solid dose manufacturing suites were also inspected and found to be compliant for formulation, granulation and encapsulation of drug products.

In separate audits by Qualified Persons, Dalton Pharma Services was also found to be compliant with GMP API manufacturing, sterile filling and testing standards for pharmaceutical products in the European Union.

“These successful inspections will allow us to continue to execute on our vision to accelerate drug development for our clients’ pharmaceutical products globally. Dalton’s ability to carry out commercial manufacture of sterile, solid dose pharmaceuticals and API provides integrated drug development and manufacturing solutions. Dalton’s reputation for its ability to complete complex drug manufacturing projects in GMP compliant facilities enhances our clients’ success in bringing the medicines of the future to the market,” said Peter Pekos, President and CEO.

Many of Dalton’s international clients have capitalized on the tremendous advantage of dealing with one CMO from start to finish; from clinical trial manufacturing through to commercial production. Dalton is strategically poised for growth within the EU as the Company adds new commercial pharmaceutical manufacturing relationships.

About Dalton Pharma Services
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

About Dalton Medicinal Chemistry
Dalton Medicinal Chemistry Incorporated (DMC) was established to offer select partners medicinal chemistry capabilities in design and synthesis of new chemical entities.
DMC focuses on quality, creativity and speed in the delivery of innovative, high quality medicinal chemistry capabilities for the identification of new chemical entities which advance our clients' drug discovery programs. Our contributions to clinical development candidate selection include SAR elucidation, design and synthesis of focused compound arrays, hit to lead, lead optimization and generation of intellectual property. DMC has full access to Dalton Pharma Services (DPS) and its world class synthetic laboratories equipped with the latest technology in modern synthetic chemistry, structural determination and purity assessment.

For further information contact:
Peter Pekos
President & CEO
Dalton Pharma Services
Tel: 416-661-2102
www.dalton.com

###

Read the full story at http://www.prweb.com/releases/Dalton/Pharma_Services/prweb3548264.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
2. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
3. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
4. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
7. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
8. Onyx Pharmaceuticals Appoints Ted W. Love, M.D., as Head of Research & Development
9. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
10. Veerman Committee Argues for Continuation of TI Pharma
11. China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Dalton Pharma Services Announces Successful Completion of Health Canada Inspection 
(Date:6/27/2016)... , ... June 27, 2016 , ... Parallel 6 ... trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module which ... with the physician and clinical trial team. , Using the CONSULT module, patients and ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:6/16/2016)... , June 16, 2016 ... size is expected to reach USD 1.83 billion ... Grand View Research, Inc. Technological proliferation and increasing ... applications are expected to drive the market growth. ... , The development of advanced multimodal ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):